Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:AEGR
- CUSIP: 00767E10
- Web: www.aegerion.com
Average Prices:
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.35
- P/E Growth: 0.00
Profitability:- Net Margins: -75.07%
- Return on Assets: -29.21%
Debt:- Debt-to-Equity Ratio: -19.22%
- Current Ratio: 1.02%
- Quick Ratio: 0.67%
Misc:
Frequently Asked Questions for Aegerion Pharmaceuticals (NASDAQ:AEGR)
What is Aegerion Pharmaceuticals' stock symbol?
Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."
How were Aegerion Pharmaceuticals' earnings last quarter?
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) issued its earnings results on Monday, May, 16th. The company reported ($1.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $1.14. The company had revenue of $35.70 million for the quarter, compared to analyst estimates of $43 million. The firm's quarterly revenue was down 39.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.55) earnings per share. View Aegerion Pharmaceuticals' Earnings History.
Where is Aegerion Pharmaceuticals' stock going? Where will Aegerion Pharmaceuticals' stock price be in 2017?
2 brokerages have issued twelve-month price objectives for Aegerion Pharmaceuticals' shares. Their forecasts range from $1.50 to $1.50. On average, they expect Aegerion Pharmaceuticals' stock price to reach $1.50 in the next year. View Analyst Ratings for Aegerion Pharmaceuticals.
What are analysts saying about Aegerion Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aegerion Pharmaceuticals stock:
- 1. Cowen and Company analysts commented, "Due to the November 29, 2016 merger of Aegerion Pharmaceuticals, Inc." (11/30/2016)
- 2. According to Zacks Investment Research, "Aegerion’s third-quarter results were encouraging, with the company reporting a narrower-than-expected loss and revenues surpassing expectations. Aegerion’s upcoming merger agreement with QLT Inc. is a big positive. It will leverage the company’s development and commercial capabilities to provide transformative treatments to patients suffering from rare but debilitating diseases. The agreement comes at a time when the company's lead drug, Juxtapid, is facing challenges due to the launch of PCSK9 inhibitors in the U.S. The company added another drug, Myalept from AstraZeneca, which boosted its portfolio. However, Aegerion is facing reimbursement hurdles for Myalept as prior authorizations are taking longer than expected and payers are requesting additional data. Moreover, the decision to withdraw Juxtapid from the EU is disappointing." (11/21/2016)
Who are some of Aegerion Pharmaceuticals' key competitors?
Some companies that are related to Aegerion Pharmaceuticals include Johnson & Johnson (JNJ), Novartis AG (NVS), Pfizer (PFE), Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY) and Valeant Pharmaceuticals International (VRX).
How do I buy Aegerion Pharmaceuticals stock?
Shares of Aegerion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aegerion Pharmaceuticals' stock price today?
One share of Aegerion Pharmaceuticals stock can currently be purchased for approximately $1.87.
MarketBeat Community Rating for Aegerion Pharmaceuticals (NASDAQ AEGR)MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)Earnings History by Quarter for Aegerion Pharmaceuticals (NASDAQ AEGR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/16/2016 | Q1 | ($0.58) | ($1.72) | $43.00 million | $35.70 million | View | Listen |  |
| 2/25/2016 | Q4 | ($0.89) | ($0.69) | $47.74 million | $49.00 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.42) | ($0.34) | $59.72 million | $67.30 million | View | N/A | |
| 8/5/2015 | Q2 | ($0.27) | ($0.01) | $58.98 million | $64.20 million | View | N/A | |
| 10/30/2014 | Q314 | ($0.18) | ($0.12) | $48.60 million | $43.70 million | View | N/A | |
| 7/29/2014 | Q214 | ($0.41) | ($0.33) | $35.40 million | $36.00 million | View | Listen | |
| 5/6/2014 | Q1 | ($0.35) | ($0.54) | $33.58 million | $27.00 million | View | Listen | |
| 2/26/2014 | Q413 | ($0.30) | ($0.14) | $24.51 million | $24.50 million | View | Listen | |
| 10/29/2013 | Q313 | ($0.50) | ($0.43) | $13.07 million | $16.30 million | View | N/A | |
| 7/30/2013 | Q2 2013 | ($0.62) | ($0.66) | $4.27 million | $6.50 million | View | N/A | |
| 11/7/2012 | Q312 | ($0.56) | ($0.59) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Aegerion Pharmaceuticals (NASDAQ:AEGR)Current Year EPS Consensus Estimate: $-3.10 EPS
Next Year EPS Consensus Estimate: $-0.43 EPS
Dividend History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aegerion Pharmaceuticals (NASDAQ:AEGR)Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 84.87%
Insider Trades by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/13/2016 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 75,000 | $1.75 | $131,250.00 | |
| 9/12/2016 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 276,000 | $1.66 | $458,160.00 | |
| 8/19/2014 | Mark J Fitzpatrick | CFO | Buy | 1,150 | $30.64 | $35,236.00 | |
| 7/31/2014 | Marc D Beer | CEO | Buy | 10,000 | $33.65 | $336,500.00 | |
| 6/3/2014 | Marc D Beer | CEO | Buy | 10,000 | $30.12 | $301,200.00 | |
| 5/27/2014 | Marc D Beer | CEO | Buy | 10,000 | $31.59 | $315,900.00 | |
| 5/20/2014 | Marc Beer | CEO | Buy | 10,000 | $30.53 | $305,300.00 | |
| 5/8/2014 | Anne Vanlent | Director | Buy | 4,000 | $33.78 | $135,120.00 | |
| 5/8/2014 | Marc Beer | CEO | Buy | 30,000 | $35.31 | $1,059,300.00 | |
| 4/30/2014 | Craig Fraser | Insider | Sell | 2,250 | $43.55 | $97,987.50 | |
| 3/31/2014 | Craig Fraser | Insider | Sell | 2,250 | $46.20 | $103,950.00 | |
| 3/14/2014 | Mark Sumeray | Insider | Sell | 2,000 | $51.34 | $102,680.00 | |
| 2/11/2014 | Craig Fraser | Insider | Sell | 2,250 | $67.00 | $150,750.00 | |
| 12/16/2013 | Mark Sumeray | Insider | Sell | 2,000 | $66.34 | $132,680.00 | |
| 10/30/2013 | Marc D Beer | CEO | Sell | 40,000 | $87.79 | $3,511,600.00 | |
| 10/29/2013 | Sandford D Smith | Director | Sell | 2,502 | $95.00 | $237,690.00 | |
| 10/15/2013 | Mark Sumeray | Insider | Sell | 2,000 | $80.33 | $160,660.00 | |
| 10/7/2013 | Mark Sumeray | Insider | Sell | 3,500 | $93.17 | $326,095.00 | |
| 9/16/2013 | Mark Sumeray | Insider | Sell | 2,000 | $89.77 | $179,540.00 | |
| 9/5/2013 | Perceptive Advisors Llc | Major Shareholder | Sell | 750,000 | $89.20 | $66,900,000.00 | |
| 8/21/2013 | David Scheer | Director | Sell | 20,000 | $84.58 | $1,691,600.00 | |
| 8/16/2013 | Mark Sumeray | Insider | Sell | 2,000 | $88.71 | $177,420.00 | |
| 8/15/2013 | Marc Beer | CEO | Sell | 60,000 | $88.54 | $5,312,400.00 | |
| 8/14/2013 | Mark Fitzpatrick | CFO | Sell | 7,500 | $93.44 | $700,800.00 | |
| 8/12/2013 | Sandford Smith | Director | Sell | 10,000 | $92.32 | $923,200.00 | |
| 7/15/2013 | Mark Sumeray | Insider | Sell | 2,000 | $78.77 | $157,540.00 | |
| 6/17/2013 | Mark Sumeray | Insider | Sell | 6,000 | $65.27 | $391,620.00 | |
| 5/15/2013 | Mark Sumeray | Insider | Sell | 6,000 | $47.32 | $283,920.00 | |
| 2/1/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $27.79 | $1,389,500.00 | |
| 1/18/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $27.62 | $1,381,000.00 | |
| 1/17/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $26.73 | $1,336,500.00 | |
| 1/11/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 475,000 | $27.07 | $12,858,250.00 | |
| 12/4/2012 | Perceptive Advisors Llc | Major Shareholder | Buy | 20,000 | $21.27 | $425,400.00 | |
| 11/29/2012 | Perceptive Advisors Llc | Major Shareholder | Buy | 30,000 | $22.71 | $681,300.00 | |
| 11/28/2012 | Perceptive Advisors Llc | Major Shareholder | Buy | 150,000 | $21.25 | $3,187,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Latest Headlines for Aegerion Pharmaceuticals (NASDAQ:AEGR)
| Source: |
|
Aegerion Pharmaceuticals (AEGR) Chart for Wednesday, July, 26, 2017
